GLUEMonte Rosa Therapeutics, Inc.

Nasdaq monterosatx.com


$ 4.16 $ -0.09 (-2.12 %)    

Thursday, 23-May-2024 11:47:47 EDT
QQQ $ 454.82 $ -1.82 (-0.39 %)
DIA $ 398.57 $ -2.68 (-0.67 %)
SPY $ 530.36 $ -1.50 (-0.28 %)
TLT $ 91.26 $ -0.78 (-0.86 %)
GLD $ 225.37 $ -2.01 (-0.92 %)
$ 4.21
$ 4.25
$ 4.14 x 200
$ 0.00 x 0
$ 4.16 - $ 4.30
$ 2.44 - $ 8.84
174,580
na
253.26M
$ 2.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-reiterates-outperform-on-monte-rosa-therapeutics-maintains-11-price-target

Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $11 price t...

 monte-rosa-therapeutics-will-present-preclinical-data-at-digestive-disease-week-2024-data-showed-that-mrt-6160-mediated-degradation-of-vav1-inhibited-disease-progression-in-a-t-cell-transfer-murine-model-of-colitis

VAV1 is a key signaling protein downstream of both the T-and B-cell receptors and its degradation has potential to treat multip...

 monte-rosa-therapeutics-reports-pricing-of-100m-public-offering

The company announced the pricing of an underwritten public offering of 10.638 million shares of its common stock at a public o...

 monte-rosa-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-no-size-or-amount-disclosed

Monte Rosa Therapeutics, Inc. ("Monte Rosa") (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel mol...

 why-westport-fuel-systems-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected ...

 monte-rosa-therapeutics-q4-eps-058-misses-033-estimate-cash-balance-of-237m-is-expected-to-provide-cash-runway-into-first-half-of-2026

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimat...

 monte-rosa-therapeutics-ai-and-machine-learning-platform-is-adding-significant-value-creation-in-cancer-research-analyst

Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the comp...

 wedbush-initiates-coverage-on-monte-rosa-therapeutics-with-outperform-rating-announces-price-target-of-11

Wedbush analyst Robert Driscoll initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform rating and ann...

 veradigm-aehr-test-systems-saratoga-investment-and-other-big-stocks-moving-lower-on-wednesday

U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NA...

 monte-rosa-therapeutics-announced-cash-position-expected-to-fund-operations-into-h1-2026

Monte Rosa Therapeutics (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-ba...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION